Type:10 Capsules
Generic Name:Acitretin
Manufacturer:Opsonin Pharma Limited
Price:৳450.00
Oral Darier's disease Adult: Initially, 10 mg daily for 2-4 wk. Max: 50 mg/day. Congenital icthyosis Adult: Initially, 25-30 mg daily for 2-4 wk before dose adjustments are done. Usual range: 25-50 mg daily for further 6-8 wk. Max: 75 mg daily for short periods. Severe psoriasis Adult: Initially, 25-30 mg daily for 2-4 wk before dose adjustments are done. Usual range: 25-50 mg daily for further 6-8 wk. Max: 75 mg daily for short periods. Severe lichen planus Adult: Initially, 25-30 mg daily for 2-4 wk before dose adjustments are done. Usual range: 25-50 mg daily for further 6-8 wk. Max: 75 mg daily for short periods.
Concomitant use with keratolytics or high dose vitamin A. Reduces anticoagulant effect of coumarins e.g. warfarin. Concomitant use of microdised progestin oral contraceptives. Concomitant use of methotrexate can potentiate hepatotoxicty. Concomitant use with tetracycline.
Female patients to avoid alcohol during and 2 mth after treatment. Avoid blood donation during therapy or at least 1-3 yr after stopping therapy. Children. Radiographic treatment for prolonged therapy. Therapy should not last >6 mth. Monitor plasma lipid and glucose levels (especially diabetics) regularly. Monitor LFTs. Lactation: enters breast milk/not recommended.
Acitretin is an active metabolite of etretinate but its mechanism of action is unknown.
Should be taken with food. Take w/ main meals or w/ a glass of milk.
Lichen planus, Psoriasis, Congenital icthyosis, Darier's disease
Cheilitis (>75%),Alopecia (50-75%),Hypertriglyceridemia (50-75%),Skin peeling (50-75%),Dry skin (25-50%),Dysglycemia (25-50%),Increased LFT (25-50%),Nail disorder (25-50%),Pruritus (25-50%),Rhinitis (25-50%),Arthralgia (10-25%),Changes in phosphorus, potassium, sodium, & magnesium levels (10-25%),Dry mouth (10-25%),Epistaxis (10-25%),Erythematous rash (10-25%),Hepatotoxicity (10-25%),Hyperesthesia (10-25%),Paresthesia (10-25%),Paronychia (10-25%),Rigors (10-25%),Skin atrophy (10-25%),Spinal hyperostosis (10-25%),Sticky skin (10-25%),Xerophthalmia (10-25%) 1-10% Edema,Flushing,Depression,Fatigue,Headache,Insomnia,Somnolence,Abdominal pain,Anorexia,Diarrhea,Gingivitis,Increased appetite,Nausea,Stomatitis,Vomiting,Hot flashes,Vision changes,Corneal epithelial abnormality,Sinusitis Potentially Fatal: Phototoxicity, jaundice, hepatitis and hepatotoxity.
Pregnancy (before the start, during and at least 2-3 yr after cessation of therapy), lactation. Hepatic and renal impairment. Hyperlipidaemia.
